



## *Media Release*

**FOR IMMEDIATE RELEASE**

**Contact Synosia Therapeutics**

In Europe:

Julie Walters at Media Speak

Tel: +44 (0) 1494 753 990

Mobile +44 (0) 775 3626967

[julie.walters@mediaspeak.com](mailto:julie.walters@mediaspeak.com)

In US:

Michele Parisi at Media Speak

Tel: +1 925 864 5028

[michele.parisi@mediaspeak.com](mailto:michele.parisi@mediaspeak.com)

### **Synosia Therapeutics Announces Appointment of Chief Medical Officer**

**South San Francisco CA, May 16, 2007** - Synosia Therapeutics today announced that it has appointed Stephen I. Bandak, M.B./B.S./M.R.C.P, as the company's new chief medical officer, effective immediately.

Dr. Bandak most recently served as vice president of medical and regulatory affairs with Novavax, Inc. in Rockville, MD., but the majority of his career was with pharmaceutical giant Eli Lilly. In his 26 years with Lilly, he served in a variety of positions in the United States, Canada and Europe, creating and executing clinical strategies and leading the development of new products, formulations and indications.

"With his depth of experience in the CNS area, having Dr. Bandak as part of our management team certainly enhances our capacity to deliver in the notoriously difficult area of CNS drug development," said Synosia Chief Executive Officer and President Dr. Ian Massey. "His vast portfolio of work around the world, including the design and conduct of clinical studies, building a clinical research capability and successfully negotiating with regulatory authorities, makes him a valuable addition to Synosia."

Dr Bandak replaces Mark Moran, M.D./M.B.A., a founder of Synosia who has been serving as chief medical officer since its creation. Dr Moran will continue to work with Synosia in the capacity of chief medical advisor.

"It's an exciting opportunity to be joining Synosia at this time," said Dr. Bandak. "In less than six months since launching the company, they have secured six compounds, most clinically enabled and many with multiple potential indications, to form a most promising pipeline of drug candidates in CNS development."

Dr. Bandak was educated and trained in Guy's Hospital Medical School, University of London and did his internship and internal medicine residency at Guy's Group Hospitals in London and neurology residency at the Royal Free Hospital in London.

**About Synosia Therapeutics**

Synosia Therapeutics is a privately-owned, drug development company, focused on developing new treatments for disorders of the central nervous system. Its leadership team has over 180 years of combined experience in drug development. Synosia has offices in Basel, Switzerland, and is headquartered in South San Francisco, CA. The company was spun out of EuroVentures Inc., a wholly-owned incubator of Versant Ventures, and recently changed its name from Synosis Therapeutics.

Synosia Therapeutics has raised \$32.5 million funding from Versant Ventures (Menlo Park, CA), Abingworth Management (London), 5AM Ventures (Menlo Park, CA) and Novo A/S (Copenhagen, Denmark). For more information, visit [www.synosia.com](http://www.synosia.com)

ENDS